Endocrine cells in the oxyntic mucosa of the stomach in patients with irritable bowel syndrome

Figure 1 Ghrelin cell densities (A) and ghrelin immunoreactivity intensities (B) in the oxyntic mucosa of the stomach of controls and IBS-total, IBS-D, IBS-M and IBS-C patients. ^aP < 0.05, and ^dP < 0.01 vs controls. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome.

Figure 2 Ghrelin-immunoreactive cells in a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.

Figure 3 Correlations of ghrelin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome symptom questionnaire. IBS: Irritable bowel syndrome.

Figure 4 Serotonin cell densities (A) and serotonin immunoreactivity intensities (B) in IBS-total, IBS-D, IBS-M and IBS-C patients. ^aP < 0.05, ^bP < 0.01 vs controls. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome.

Figure 5 Serotonin cells in the oxyntic mucosa of the stomach of a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.

Figure 6 Correlations of serotonin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome symptom questionnaire. IBS: Irritable bowel syndrome.

Figure 7 Somatostatin cell densities (A) and somatostatin immunoreactivity intensities (B) in IBS-total, IBS-D, IBS-M and IBS-D patients. The symbols are the same as in Figures 1 and 4. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome. ^aP < 0.05, ^bP < 0.01 and ^dP < 0.01 vs controls.

Figure 8 Somatostatin cells in the oxyntic mucosa of the stomach of a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.

Figure 9 Correlations of somatostatin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome symptom questionnaire. IBS: Irritable bowel syndrome.